Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Rectal Neoplasms 2Neurotoxicity Syndromes 2Colorectal Neoplasms 2Colonic Neoplasms 2Primary Immunodeficiency Diseases 1Pain 1Neoplasms 1Infections 1Epstein-Barr Virus Infections 1Breast Neoplasms 1

Interventions

Gemcitabine 57Paclitaxel 50Cyclophosphamide 45pembrolizumab 44Carboplatin 41Bevacizumab 38Cisplatin 33Docetaxel 31Fluorouracil 30Nivolumab 29Capecitabine 29Pemetrexed 24Irinotecan 24Oxaliplatin 23Dexamethasone 23Ipilimumab 22Leucovorin 21Radiotherapy 20Sorafenib 19Doxorubicin 19Everolimus 18Cetuximab 18fludarabine 17Albumin-Bound Paclitaxel 17trametinib 15Sunitinib 15Rituximab 15Erlotinib Hydrochloride 15130-nm albumin-bound paclitaxel 15Prednisone 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Neoplasms × Magnesium Sulfate × Clear all
NCT02496676 2022-03-02

Magnesium Supplementation in People With XMEN Syndrome

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
8 enrolled 7 charts

Primary Immunodeficiency Diseases, Infections, Neoplasms, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡